Discover PANGAEA’s world
Our PhDs participate in scientific publications in peer-reviewed journals
Our latest news, events, meetings, announcements and stories
OUR LATEST SCIENTIFIC PUBLICATIONS
- 2024
- 2023
- 2022
- 2021
- 2020
- 2019
- 2018
- García-Roman S, Garzón-Ibáñez M, Bertrán-Alamillo J, Jordana-Ariza N, Giménez-Capitán A, et al.
“Vaccine antibodies against a synthetic epidermal growth factor variant
enhance the antitumor effects of inhibitors targeting the MAPK/ERK and
PI3K/Akt pathways”. PMCID: PMC10818253.
- González-Cao M, Pedraz C, Molina-Vila MÁ, Rosell R.
“Pangaea Oncology, Dexeus University Hospital: bridging preclinical and clinical research”. PMCID: PMC10809738.
- Rosell R, Codony-Servat J, González J, Santarpia M, Giménez-Capitán A, Molina-Vila MA, et al.
“KRAS G12-mutant driven non_small cell lung cancer (NSCLC)”. PMID: 38072173.
- Rosell R, Pedraz-Valdunciel C, Jain A, Shivamallu C, Aguilar A, et al.
“Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutantions or oncogenic fusions”. 33:3, 171-182 (2024).
- Bertran-Alamillo J, Giménez-Capitan A, Román R, Talbot S, Whiteley R, et al.
- Giménez-Capitán A, Sánchez-Herrero E, Robado de Lope L, Aguilar-Hernández A, Sullivan I, et al.
“Detecting ALK, ROS1, and RET fusions and the METAex14 splicing variant in liquid biopsies of non-small-cell lung cancer patients using RNA-based techniques”. PMCID: PMC10483610.
- Reischmann N, Schmelas C, Molina-Vila MÁ, Jordana-Ariza N, Kuntze D.
“Gene expression signatures in conjunctival fornix aspirates of patients with dry eye disease associated with Meibomian gland dysfunction. A proof-of-concept study”. PMID: 37524297.
- Reischmann N, Schmelas C, Molina-Vila MÁ, Jordana-Ariza N, Kuntze D.
“Overcoming MET-mediated resistance in oncogene-driven NSCLC”. PMCID: PMC10391663.
- Rafael Rosell & Peng Cao
“Promising outlook with sugemalimab in non-small-cell lung cancer”.
Lancet Oncology 2022 Published Online January 14, (Vol 23): 186-187, 2022. IF: 41.316.
- Rafael Rosell, Maria González-Cao
“Ablating lung cancer, knowing the tumor better”. The Lancet Regional Health – Europe 2022;22: 100494.
- Rafael Rosell, Andrés F. Cardona, Oscar Arrieta, María González-Cao
“Classification of atypical EGFR mutations in non-small-cell lung cancer”. Ann Oncol 2022 Mar 21;S0923-7534(22)00389-1. Vol 33, Issue 6, P571-573, June 01, 2022 IF: 51.769.
- AF Cardona, M González-Cao, O Arrieta & Rafael Rosell.
“Location of EGFR exon 20 insertions matters”. Cancer Cell 2022. IF: 31.743.
- M González-Cao et al.
“COVID-19 in Melanoma Patients: Results of the Spanish Melanoma Group Registry, GRAVID study”
Journal of the American Academy of Dermatology 2021, 84 (5): 1412-1415. IF: 8.277.
- Rosell R, Cardona AF.
“Poziotinib treatment in intractable NSCLC: EGFR and HER2 exon 20 insertion mutation disease” European Journal of Cancer, 2021. IF: 7.275.
- Rosell R, González-Cao M.
“Cemiplimab monotherapy in advanced non-squamous and squamous NSCLC” Lancet 2021. Vol 397 February 13: 557-559. IF: 60.392.
- Bracht, J.W.P., Gimenez-Capitan, A., Huang, CY. et al.
“Analysis of extracellular vesicle mRNA derived from plasma using the nCounter platform” Sci Rep 11, 3712 (2021). IF: 3.99.
- Rosell R, Ito M.
“Neoadjuvant atezolizumab plus chemotherapy in resectable
non-small-cell lung cancer”
Lancet Oncology, 2020 Jun;21(6):736-738. IF: 35. 386.
- Rosell R, Cardona AF.
“Poziotinib treatment in intractable NSCLC: EGFR and HER2 exon 20 insertion mutation disease” European Journal of Cancer, 2021. IF: 7.275.
- Maria González-Cao; Javier Martinez-Picado; Rafael Rosell.
“Safety of anti-PD-L1 inhibition in HIV-1-infected cancer patients” (Response letter of A. Dekker). JAMA Oncology 2020. (Accepted). IF: 22.416.
- Rafael Rosell, Imane Chaib, Mariacarmela Santarpia.
“Targeting MET amplification in EGFR-mutant non-small-cell lung cancer” Lancet Respir Med. 2020 Published online May 22, 2020. IF: 15.780.
- Karachaliou N, Fernandez Bruno M, Bracht JWP, Rafael Rosell.
“Profile of alectinib for the treatment of ALK-positive Non-Small Cell Lung Cancer (NSCLC): patient selection and perspectives” OncoTargets and Therapy 2019. IF: 2.656.
- Niki Karachaliou, Manuel Fernandez-Bruno, Jillian Wilhelmina Paulina Bracht, Rafael Rosell.
“EGFR first- and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients” Transl Cancer Res 2019; 8 (Suppl 1): S23-S47 IF: 1.2.
- Jillian Wilhelmina Paulina Bracht, Niki Karachaliou, Jordi Berenguer, Manuel Fernandez-Bruno, Martyna Filipska, Carlos Pedraz-Valdunciel, Carles Codony-Servat, Jordi Codony-Servat, Rafael Rosell.
“PIM-1 inhibition with AZD1208 to prevent osimertinibinduced resistance in EGFR-mutation positive non-small cell lung cancer.” Journal of Cancer Metastasis and Treatment 2019.
- Andrés F. Cardona, Alejandro Ruiz-Patiño, Luisa Ricaurte, Leonardo Rojas, Zyanya Lucia Zatarain-Barrón, Oscar Arrieta, Rafael Rosell.
“Human Papillomavirus Infection and Lung Cancer Current Perspectives in Human Papillomavirus” (BOOK CHAPTER)
IntechOpen, 2019.
- Irene Moya-Horno, Santiago Viteri, Rafael Rosell
“Unsuspected N2-positive non-small cell lung cancer after complete resection: is there a place for multimodal adjuvant therapy?” AME Medical Journal. February 2018.
- Niki Karachaliou, Imane Chaib, Andres Felipe Cardona, Jordi Berenguer, Jillian Wilhelmina Paulina Bracht, Jie Yang, et al.
“Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-small cell Lung Cancer Associated With Poor Prognosis” EBioMedicine, February 2018, Epub ahead of print.
- Karachaliou N, Gonzalez-Cao M, Crespo G, et al.
“Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients” AME Medical Journal. Therapeutic Advances in Medical Oncology, January 18, 2018.
- Irene Moya-Horno, Santiago Viteri, Niki Karachaliou, Rafael Rosell
“Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)” Therapeutic Advances in Medical Oncology, January 9, 2018.